ImmunityBio (IBRX) Change in Acquisitions & Divestments (2015 - 2026)

ImmunityBio (IBRX) has 12 years of Change in Acquisitions & Divestments data on file, last reported at $79.4 million in Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $79.4 million, up 1383.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $105.0 million (down 12.5% YoY), and the FY2025 annual result was $30.9 million, down 73.24% from the prior year.
• Change in Acquisitions & Divestments rose to $79.4 million in Q1 2026 per IBRX's latest filing, from $30.9 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $99.1 million in Q2 2022 and troughed at -$79.7 million in Q3 2022.
• A 5-year average of $18.6 million and a median of $9.8 million in 2022 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2022 and 2024: Change in Acquisitions & Divestments slumped 355.46% in 2022, then soared 48459.8% in 2024.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $56000.0 in 2022, then soared by 382.14% to $270000.0 in 2023, then surged by 6579.26% to $18.0 million in 2024, then surged by 71.49% to $30.9 million in 2025, then soared by 156.68% to $79.4 million in 2026.
• Business Quant data shows IBRX's Change in Acquisitions & Divestments at $79.4 million in Q1 2026, $30.9 million in Q4 2025, and -$5.4 million in Q2 2025.